The Innovation Reduction Act with Allan Shaw
Business Of Biotech
00:00
The Impact of the IRA on the Opportunity to Repurpose Existing Drugs
It's also been said that the IRA encourages pharma companies to stop looking for new applications of existing drugs. The last five years or so of your exclusivity period represents about 50%. So once you cut that tail off, there's no real incentive to invest and extend these drugs in terms of other indications. And it effectively pushes the more cost effective small molecules, which are less costly to manufacture.
Transcript
Play full episode
